Clinical trials: Stem Cell Transplants
BK Virus Infection
Most Closely Human Leukocyte Antigen (HLA)-Matched BK Virus-specific T Lymphocytes (Viralym-B)
Patients enrolled on this study will have received a stem cell transplant. After a transplant, while the immune system grows back the patient is at risk for infection.
- Trial name
- NCT02313844
- Testing
- Viralym-B
- Where
- 2 sites in United States
- Sponsor
- AlloVir
Lymphoma, Multiple Myeloma
Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma
The purpose of this study is to see if Isatuximab can alter the immune system in patients with multiple myeloma or lymphoma upon recovery from the autologous stem cell transplantation.
- Conditions
- Lymphoma, Multiple Myeloma, Non-Hodgkin Lymphoma, Relapsed Hodgkin's Disease, Adult
- Trial name
- NCT05346809
- Testing
- Isatuximab, Standard Procedures
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- Divaya Bhutani
Acute Myeloid Leukemia, Essential Thrombocythemia
Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
This phase II trial studies how well decitabine with ruxolitinib, fedratinib, or pacritinib works before hematopoietic stem cell transplant in treating patients with accelerated/blast phase myeloproliferative neoplasms (tumors).
- Conditions
- Acute Myeloid Leukemia, Essential Thrombocythemia, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm
- Trial name
- NCT04282187
- Testing
- Decitabine, Ruxolitinib, Fedratinib
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Washington
HCMV
Efficacy and Safety Study of CSJ148 in Stem Cell Transplant Patients
This study is designed to test if CSJ148 can prevent HCMV replication after stem cell transplantation.
- Trial name
- NCT02268526
- Testing
- CSJ148
- Where
- 17 sites in United States, Belgium and 4 more
- Volunteers
- 86 people
- Sponsor
- Novartis Pharmaceuticals
Allogeneic Stem Cell Transplant, Graft Versus Host Disease
Nutrition and Outcomes of Hematopoietic Cell Transplantation (HCT)
Retrospective case-note review to determine if nutrition via the enteral compared to the parenteral route results in better outcomes after haematopoietic cell transplantation.
- Conditions
- Allogeneic Stem Cell Transplant, Graft Versus Host Disease, Hematologic Malignancy, Stem Cell Transplant Complications
- Trial name
- NCT03419078
- Volunteers
- 484 people
- Sponsor
- Imperial College Healthcare NHS Trust
Relapsed Hematologic Malignancy
Infusion of Donor Derived Cytokine Induced Killer (CIK) Cells in Hematological Patients Relapsed After Haploidentical Stem Cell Transplant
The haematological neoplasia relapse is the cause of higher mortality after allogeneic stem cell transplantation (HSCT). When transplantation fails the most common therapeutic strategy is to increase the antitumor activity of the…
- Trial name
- Haplo-CIK (NCT03821519)
- Testing
- donor-derived CIK cells
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- A.O. Ospedale Papa Giovanni XXIII
Hematopoietic Stem Cell Transplantation, Bacterial Infections and Mycoses
Safety of a Single Dose of 5 mg of hLF1-11 Given to Autologous Haematopoietic Stem Cell Transplant Recipients
The safety and tolerability of hLF 1-11 has to be established first in HSCT recipients who are at risk of developing, but have not yet developed, infectious complications due to invasive fungal disease.
- Trial name
- NCT00509938
- Testing
- human lactoferrin peptide 1-11
- Where
- Netherlands
- Volunteers
- 8 people
- Sponsor
- AM-Pharma
Graft vs Host Disease
Atorvastatin for the Prophylaxis of Acute GVHD in Patients Undergoing Matched Sibling Allogeneic Transplantation
Atorvastatin for prevention of acute GVHD
- Trial name
- NCT01175148
- Testing
- Atorvastatin calcium (Lipitor)
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- West Virginia University
Multiple Sclerosis
Allogeneic Stem Cell Transplantation for the Treatment of Multiple Sclerosis
The goal of this research study is to establish chimerism with the goal to halt disease progression in patients with Multiple Sclerosis.
- Trial name
- NCT00497952
- Testing
- hematopoetic stem cell infusion
- Sponsor
- Talaris Therapeutics Inc.
Allogeneic Hematopoietic Stem Cell Transplant Recipient, Hematopoietic and Lymphoid Cell Neoplasm
Gardasil 9 Vaccine in Preventing HPV Infection in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
This phase IV trial studies how well Gardasil 9 vaccine works in preventing human papillomavirus (HPV) infection in patients with hematologic malignancies who are undergoing donor stem cell transplant.
- Trial name
- NCT03023631
- Testing
- Recombinant Human Papillomavirus Nonavalent Vaccine
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- M.D. Anderson Cancer Center
Malignancies, Hematologic
Pretransplant Evaluation by Supportive Care Team for Patients Undergoing HCT for Hematological Malignancies
This is a feasibility study of pre-transplant involvement of a palliative care provider in the setting of HCT. Although this is primarily a feasibility pilot, the investigators will explore how patients are affected by the…
- Trial name
- NCT02321345
- Testing
- Palliative Care Support
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Medical College of Wisconsin
Thrombotic Microangiopathies, Atypical Hemolytic Uremic Syndrome
Eculizumab to Treat Thrombotic Microangiopathy/Atypical Hemolytic Uremic Syndrome -Associated Multiple Organ Dysfunction Syndrome in Hematopoietic Stem Cell Transplant Recipients
Hematopoietic stem cell transplantation (HCT)-associated thrombotic microangiopathy (TMA) is an understudied complication of HCT that significantly affects transplant related morbidity and mortality.
- Conditions
- Thrombotic Microangiopathies, Atypical Hemolytic Uremic Syndrome, Multiple Organ Dysfunction Syndrome
- Trial name
- NCT03518203
- Testing
- Eculizumab
- Where
- 3 sites in United States
- Volunteers
- 23 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Phase II Study of Azacitidine and Sargramostim as Maintenance Treatment for Poor-Risk AML or MDS
To determine the impact of maintenance therapy in patients with MDS/AML in remission.
- Trial name
- NCT01700673
- Testing
- Azacitidine, Sargramostim
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Thrombocytopenia, Stem Cell Transplant Complications
Prolonged Isolated Thrombocytopenia After Allo-SCT : N-acetyl-L-cysteine (NAC) Versus Supportive Therapy
Isolated prolonged thrombocytopenia (PT) is a common complication after allogeneic stem cell transplantation with significant poor prognosis. No standard treatment is available.
- Trial name
- NCT03391856
- Testing
- N-acetyl-L-cysteine (NAC), supportive therapy
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Peking University People's Hospital
Leukemia, Myelodysplastic Syndromes
Laboratory-Treated Lymphocyte Infusion After Haploidentical Donor Stem Cell Transplant
RATIONALE: Giving total-body irradiation and chemotherapy, such as thiotepa and fludarabine, before a donor stem cell transplant helps stop the growth of cancer or abnormal cells.
- Trial name
- NCT00376480
- Testing
- anti-thymocyte globulin, peripheral blood lymphocyte therapy, fludarabine phosphate
- Where
- 6 sites in United States
- Volunteers
- 19 people
- Sponsor
- Dana-Farber Cancer Institute
Multiple Myeloma
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
The study is designed as a Phase III, multi-center trial of tandem autologous transplants versus the strategy of autologous followed by Human Leukocyte Antigen (HLA)-matched sibling non-myeloablative allogeneic transplant.
- Trial name
- NCT00075829
- Testing
- One Autologous Transplant, Non-Myeloablative Allogeneic Transplant, Second Autologous Transplant
- Where
- 36 sites in United States
- Volunteers
- 710 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Hematopoietic Stem Cell Transplant
Positive Psychology Intervention for Hematopoietic Stem Cell Transplantation Survivors
This randomized clinical trial is evaluating the impact of a positive psychology intervention (PATH) on anxiety symptoms, depression symptoms, and quality of life in survivors of hematopoietic stem cell transplant (HSCT) compared…
- Trial name
- PATH-4 (NCT06328127)
- Testing
- PATH
- Where
- 3 sites in United States
- Volunteers
- 400 people
- Sponsor
- Brigham and Women's Hospital
Leukemia, Lymphoma
Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer
RATIONALE: Giving low doses of chemotherapy before a donor stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
- Trial name
- NCT00818961
- Testing
- alemtuzumab, graft-versus-tumor induction therapy, rituximab
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Northside Hospital, Inc.
Cancer Distress, Cancer Coping
Aromatherapy Inhaler Use for HSCT Distress
This randomized controlled trial will evaluate the feasibility and acceptability of an inhaled aromatherapy stick for patients during the acute inpatient phase after hematopoietic cell transplantation (HCT) .
- Conditions
- Cancer Distress, Cancer Coping, Hematopoetic Stem Cell Transplant, Aromatherapy
- Trial name
- NCT05302583
- Testing
- Aromatherapy Stick, Standard of Care
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Stanford University
Transplant Associated Microangiopathy TAM, Transplant Complication
Assessing the Incidence of Transplant Associated Thrombotic Microangiopathy (TA-TMA) in Adult Patients Undergoing Allogeneic Stem Cell Transplant (SCT)
The goal of this observational study is to learn about the incidence of Transplant Associated Thrombotich Microangiopathy (TA-TMA), which is a known but underreported complication of Allogeneic Stem Cell Transplant (SCT).
- Trial name
- NCT07381205
- Where
- United States
- Volunteers
- 85 people
- Sponsor
- Manuel Ricardo Espinoza-Gutarra
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.